Watchlist Price Alert

Vericel Corporation (VCEL)

NASDAQ: VCEL · Real-Time Price · USD

41.52

1.05 (2.59%)

At close: May 08, 2025, 3:31 PM

2.59% (1D)

Bid	41.5
Market Cap	2.08B
Revenue (ttm)	237.22M
Net Income (ttm)	10.36M
EPS (ttm)	0.2
PE Ratio (ttm)	207.6
Forward PE	51.93
Analyst	Strong Buy

Ask	41.58
Volume	771,873
Avg. Volume (20D)	475,193
Open	40.25
Previous Close	40.47
Day's Range	38.62 - 42.18
52-Week Range	37.39 - 63.00
Beta	1.32

About VCEL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol VCEL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for VCEL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Vericel has released their quartely earnings on May 8, 2025:

Revenue of $52.6M misses estimates by $1.26M, with 2.57% YoY growth.

EPS of -0.23 misses estimates by -0.10, with -187.50% YoY decline.

Next Earnings Release

Vericel Corporation is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 hours ago New

VCEL stock has given up its prior loss. Vericel sh... Unlock content with Pro Subscription

4 hours ago New

Vericel shares are trading lower after the company reported worse-than-expected Q1 financial results.

News

5 hours ago · seekingalpha.com

Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript

Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Par...

Just now · zacks.com

Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates

Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

2 months ago · seekingalpha.com

Vericel: Scalable Growth With Strong Margins

Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials inc...

2 months ago · seekingalpha.com

Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript

Vericel Corporation (NASDAQ:VCEL ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Nick Colangelo - CEO Joe Mara - CFO Eric Burns - VP, Finance and IR Conference Cal...

2 months ago · zacks.com

Vericel Corporation (VCEL) Tops Q4 Earnings Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.26 per share a year ago.